Illumina (ILMN) Tops Q3 EPS by 25c
Get Alerts ILMN Hot Sheet
Revenue Growth %: -3.7%
Financial Fact:
Selling, general and administrative: 139.15M
Today's EPS Names:
CPSS, HARL, MCET, More
Join SI Premium – FREE
Illumina (NASDAQ: ILMN) reported Q3 EPS of $1.02, $0.25 better than the analyst estimate of $0.77. Revenue for the quarter came in at $794 million versus the consensus estimate of $715.91 million.
“Our business accelerated in the third quarter with sequencing consumable revenue growing 29% from the second quarter,” said Francis deSouza, Chief Executive Officer. “We’re also making progress incorporating genomics into the standard of care in non-invasive pre-natal testing, oncology therapy selection, and genetic disease diagnosis. Looking forward, we believe our planned acquisition of GRAIL will catalyze a new era of early cancer detection, transforming cancer survivability and opening up the largest clinical application of genomics we’ve seen.”
GUIDANCE:
As previously announced, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic.
For earnings history and earnings-related data on Illumina (ILMN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adidas (ADDYY) stock rises after outlook boost
- Sunoco LP (SUN) Completes Acquisition of European Liquid Fuels Terminals and Divestiture of West Texas Assets; Reaffirms 2024 Adjusted EBITDA Guidance Range
- LVMH achieves 3% organic revenue growth in the first quarter
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!